Improving resectability and survival in patients with primary duodenal carcinoma

Delcore, Romano; Thomas, James H.; Forster, Jameson; Hermreck, Arlo S.

doi:10.1016/s0002-9610(05)80668-3

Cited by 62 publications

(56 citation statements)

References 16 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…Duodenal cancers commonly occur in the ampullary or periampullary regions of the descending duodenum [10]; however, these tumors are occasionally found in other portions of the duodenum [11]. If caught early, the preferred treatment for resectable lesions in the second and third portions of the duodenum is a pancreaticoduodenectomy with en bloc resection of adjacent tissues, including regional lymph nodes [12].…”

Section: Discussionmentioning

confidence: 99%

Signet Ring Cell Carcinoma of the Duodenal Bulb With Metastases to the Ovaries and the Colon: A Case Report

Henry

2013

J Med Cases

View full text Add to dashboard Cite

show abstract

Section: Discussionmentioning

confidence: 99%

Signet Ring Cell Carcinoma of the Duodenal Bulb With Metastases to the Ovaries and the Colon: A Case Report

Henry

2013

J Med Cases

View full text Add to dashboard Cite

show abstract

“…O quadro clínico é inespecífico e de início insidioso, podendo ser interpretado como decorrente de condições benignas do sistema digestório e tratados pelos próprios pacientes ou pelos médicos sem investigação detalhada 7,9,10,16 . Os sinais e sintomas mais freqüentes estão relacionados à sub-oclusão intestinal crô-nica, tais como dor abdominal relatada por 31,8% a 56%, empachamento e vômitos pós-prandiais referidos por 27,3% a 51,8%, emagrecimento citado em 10,6% a 62% das vezes e anemia constatada em 27,3% a 60,6% dos doentes 6,8,14 .…”

Section: D D D Discussão Iscussão Iscussão Iscussão Iscussãounclassified

“…Para as lesões neoplásicas localizadas na segunda porção duodenal, a duodenopancreatectomia com linfonodectomia é o tratamento de escolha 8,9 . A ressecção segmentar é indicada para os tumores da terceira e quarta porções duodenais, com excelente taxa de sobrevivência e baixa morbidade pós-operatória 3,7,8,9,10,11 . A duodenopancreatectomia tem morbidez maior que a ressecção segmentar duodenal 10,13 .…”

Section: D D D Discussão Iscussão Iscussão Iscussão Iscussãounclassified

“…A ressecção segmentar é indicada para os tumores da terceira e quarta porções duodenais, com excelente taxa de sobrevivência e baixa morbidade pós-operatória 3,7,8,9,10,11 . A duodenopancreatectomia tem morbidez maior que a ressecção segmentar duodenal 10,13 . Na nossa casuística, três doentes foram submetidos à ressecção segmentar duodenal curativa, dois dos quais tinham tumores na primeira porção duodenal e outro na terceira.…”

Section: D D D Discussão Iscussão Iscussão Iscussão Iscussãounclassified

See 1 more Smart Citation

Adenocarcinoma primário do duodeno

Siqueira¹,

Nadal²,

Rodrigues³

et al. 2002

Rev. Assoc. Med. Bras.

View full text Add to dashboard Cite

“…The standard treatment is surgery with a resection rate of 35-77%. The operative mortality of surgery with a curative intent is 0-18% and the 5-year survival is 10-62% (Delcore et al, 1993;Ouriel and Adams, 1984). The role of radiotherapy and chemotherapy is less clear.…”

mentioning

confidence: 99%

The Royal Marsden experience of small bowel adenocarcinoma treated with protracted venous infusion 5-fluorouracil

Crawley

Ross²,

Norman³

et al. 1998

Br J Cancer

View full text Add to dashboard Cite

Summary The purpose of this study was to review the efficacy of a protracted venous infusion of 5-fluorouracil (PVI 5-FU)-based chemotherapy in advanced small bowel adenocarcinoma. Data on all patients with small bowel malignancy who were seen at a single institution over a 5-year period were retrieved from the gastrointestinal unit and hospital databases, and these cases were reviewed. Eight patients with advanced small bowel adenocarcinoma received PVI 5FU-based chemotherapy. The overall response rate in assessable patients was 37.5% (3/8). The median overall survival was 13 months (range 1-28), and progression-free survival was 7.8 months (range 0-15). Overall, the treatment was well tolerated and symptomatic benefit was seen. In conclusion, PVI 5-FU has activity in this disease. This should be assessed either as a single agent or as part of a combination regimen such as epirubicin/cisplatin/PVI FU (ECF) in a multicentre randomized study.Keywords: small intestine; adenocarcinoma; 5-fluorouracil; infusional treatment Although adenocarcinoma is the most common small bowel tumour, it still represents less than 1% of gastrointestinal (GI) tract tumours. The standard treatment is surgery with a resection rate of 35-77%. The operative mortality of surgery with a curative intent is 0-18% and the 5-year survival is 10-62% (Delcore et al, 1993;Ouriel and Adams, 1984). The role of radiotherapy and chemotherapy is less clear. There are reports of prolonged survival with combination chemo-and radiotherapy following palliative bypass surgery or incomplete resection and reports suggesting a better prognosis compared with pancreatic carcinoma (Sakker and Ware, 1973;Yeung et al, 1993). Data on the use of chemotherapy alone are limited. Regimens used have been very varied, and some series have been collected over prolonged periods (Sakker and Ware, 1973;Okhusa et al, 1991). METHODSThe GI unit and hospital databases were searched for patients referred to the Royal Marsden Hospital (RMH) with malignancy of the small bowel during the period 1990-95. Pathology was reviewed at RMH before treatment. Data regarding diagnosis, treatment, toxicity and response were collected prospectively. Responses were assessed according to the WHO criteria (Miller et al, 1981). Symptomatic responses were recorded prospectively on the GI database; improvement was defined as disappearance of a symptom for >3 weeks.

show abstract

Improving resectability and survival in patients with primary duodenal carcinoma

Cited by 62 publications

References 16 publications

Signet Ring Cell Carcinoma of the Duodenal Bulb With Metastases to the Ovaries and the Colon: A Case Report

Signet Ring Cell Carcinoma of the Duodenal Bulb With Metastases to the Ovaries and the Colon: A Case Report

Adenocarcinoma primário do duodeno

The Royal Marsden experience of small bowel adenocarcinoma treated with protracted venous infusion 5-fluorouracil

Contact Info

Product

Resources

About